Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05736146
Other study ID # RI-GWI-003
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 30, 2022
Est. completion date September 2024

Study information

Verified date January 2024
Source Roskamp Institute Inc.
Contact Dakota Helgager, B.S
Phone (941) - 256 - 8019
Email dhelgager@roskampclinic.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators goals are to identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI. To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans. To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI. To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI.


Description:

Nearly 30 years later, veterans with Gulf War Illness (GWI) continue to suffer from this persistent and debilitating illness, which remains difficult to diagnose due to the heterogeneity of clinical presentation and the complexity of biological responses to hazardous chemicals to which GW veterans were exposed during the 1990-1991 Gulf War (GW). Brain imaging studies of veterans with GWI and pre-clinical animal studies of rodents with GWI show that impaired bioenergetics and inflammation can be attributed to the atrophy of the axonal white matter tracts that link the cortical gray matter regions, and the alterations of lipid/metabolite levels. The investigators recent work shows that disturbed lipid profiles in the brain and blood after GW pesticide exposure in rodents accompany neurobehavioral and bioenergetics deficits and inflammation. The mechanisms of neurotoxicity after pesticide exposure include increases in the inactivation of lipid metabolizing enzymes. This may consequently result in accumulation of lipids in the body compartments that limit their availability for use as energy substrates, contributing to bioenergetic impairments and inflammation. These metabolic changes have also been linked to individuals who possess the apolipoprotein E (APOE) ε4 allele, a risk factor of aging related cognitive decline and neurodegenerative conditions, such as Alzheimer's disease (AD). Several studies have shown a correlation between lipid transport deficits and presence of the ε4 allele. The identification of specific lipids/metabolites and the APOE ε4 allele as important biomarkers of GWI would serve to objectively assess the brain pathology of GWI and identify subgroups of GWI based on symptom patterns and GW exposures.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years and older
Eligibility Inclusion Criteria: 1. Age 35 years or older. 2. For GWI cases, served in the 1990-1991 Gulf War as active duty, national guard, or reserves and meet criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition. 3. For controls, must be a veteran in the same age range as those veterans with GWI as defined above. 4. Ability to understand written and spoken English or availability of a legal representative who can understand written or spoken English. Participants and caregiver/informants must be able to read, write and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate testing. Exclusion Criteria: 1. Diagnosed or being treated by a physician for any of the following (Steele et al, 2000) and deemed clinically significant per the discretion of the PI: 1. Cancer (except for non-melanoma skin cancers) 2. Chronic infectious disease 3. Problems resulting from postwar injuries. 4. Liver disease 5. Lupus 6. Multiple sclerosis 7. Stroke 8. Serious psychiatric condition (those associated with psychosis and/or for which the respondent had been hospitalized since 1991). 9. Dementia or any type of Parkinson's disease (PD). 2. Hospitalized in the last 5 years for alcohol or drug dependence, depression, or post-traumatic stress disorder (PTSD). 3. Female subject is either pregnant or nursing.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Boston University Boston Massachusetts
United States Palto Alto Veterans Institute for Research Palo Alto California
United States The Roskamp Institute Sarasota Florida

Sponsors (4)

Lead Sponsor Collaborator
Roskamp Institute Inc. Boston University, Palo Alto Veterans Institute for Research, United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validate Blood Biomarkers To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI. 2022-2024
Primary Identify Blood/Lipid Profiles To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI. 2022-2024
Primary Effect of Dietary, Medical and Biological Factors To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans. 2022-2024
Primary Metabolites Correlating with Cognitive Decline To identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE e4 allele among veterans with GWI. 2022-2024
See also
  Status Clinical Trial Phase
Recruiting NCT04254627 - TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset Phase 1
Terminated NCT02011542 - Probiotic (VSL #3) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT03078530 - Probiotic (Visbiome) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT04058275 - "Immunomodulation in GWI (Phlebotomy)"
Recruiting NCT04255498 - Understanding GWI: Integrative Modeling Phase 1
Completed NCT02782780 - Cognitive Behavioral Therapy for Insomnia for Gulf War Illness N/A
Recruiting NCT02983734 - D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS) Phase 2
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Recruiting NCT04046536 - rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI) N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Recruiting NCT05377242 - Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Not yet recruiting NCT05820893 - Resistant Potato Starch to Alleviate GWI Phase 2
Terminated NCT01846182 - Research Examining Gulf War Illness in Our Nations Service Members Phase 2
Active, not recruiting NCT05252949 - OEA for Targeting Lipid Metabolism in GWI N/A
Completed NCT02378025 - Treating Chronic Pain in Gulf War Illness N/A
Completed NCT02865460 - Coenzyme Q10 Phase III Trial in Gulf War Illness Phase 3
Completed NCT02909686 - Effects of Botanical Microglia Modulators in Gulf War Illness N/A
Completed NCT01291758 - Exercise in Gulf War Illness (GWI)
Completed NCT01011348 - Q10 for Gulf War Veterans N/A